To evaluate the diagnostic accuracy of FDG-PET in patients with extranodal MALT lymphoma and assessed its reliability in clinical staging and monitoring response.
Methods and Materials
A total of 70 patients of 82 sites with a histological diagnosis of extranodal MALT lymphoma were referred. All informations were obtained from a retrospective review of medical records, PET findings and data. FDG-PET imaging was performed using ECAT EXACT HR 47, ECAT ACCEL, BIOGRAPH DUO LSO (PET/CT), or Aquiduo 16 (PET/CT). Imaging was performed at 60 minutes after the intravenous administration of 185-250 MBq F18-FDG. Each patient had been fasting for at least 4 hours when imaged, and a...
Seventy patients in this study included 29 men(41.2%)and 41 women(58.8%) with a median age at diagnosis of 64 years (range 33 to 90 y)(Figure 1). The sites of MALT were the orbit (n = 34)(Figure 2), stomach (n = 22)(Figure 3), lung (n = 9), intestine (n =4) , thyroid(n=3), bone marrow (n =3) . head & neck (epipharynx, tonsil, sublingual gland, lip, larynx)(n=6), intestine (rectum, ileum,cecum)(n=4),breast (n=1), esophagus(n=1), liver (n=1)(Figure 4). The SUVmax of FDG was <1.5 at 3 sites...
The SUVmax of MALT was >1.5 at 79 sites (Sensiyivity 96.3%). We identified FDG avidity in 71.4% of extra-nodal MALT lymphoma but in 50.0% of orbital MALT. Two patients with bone marrow invasion were understaged. However, these results suggested that PET is a useful tool with which to stage, restage after therapy, or monitor disease in patients with extra- nodal MALT lymphoma.
1. Perry C,et al. Diagnostic accuracy of PET/CT in patients with extranodal marginal zone MALT lymphoma. Eur J Nucl Med Mol Imag2007;79:205-209 2.Alinari L, et al. 18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma. Leukemia & Lymphoma 2006; 47:2096-2101 3.Beal KP, et al. FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases. Ann Oncol 2005; 16:473-480 4.Bae YA, et al. Marginal zone B-cell lymphoma of...
Kazumasa Hayasaka, MD,PhD. Director in department of Nuclear Medicine, Japanese Foundation for Cancer Research, Cancer Institute Hospital.